In a pre-specified interim analysis of the Phase 2 KEYNOTE-B84 study evaluating pepinemab in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for immunotherapy of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), pepinemab induced lymphoid structures were associated with an approximate doubling of objective responses (ORR) and progression free survival (PFS) relative to historical results with checkpoint monotherapy in patients with hard-to-treat tumors that express low levels of PD-L1 (CPS<20). https://bit.ly/47fm7Z9 #SITC23 #SITC2023 #Bcells
Vaccinex’s Post
More Relevant Posts
-
📋 A regimen of PD-1 inhibitors and chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, enhance radiosensitivity, and improve local control for patients. Learn how this treatment can aid patients with #esophagealcancer:
To view or add a comment, sign in
-
📋 A regimen of PD-1 inhibitors and chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, boost radiosensitivity, and improve local control for patients. Learn how the treatment can aid patients with #esophagealcancer:
Does Induction Immunotherapy Benefit Patients With Advanced Esophageal Cancer? | Docwire News
docwirenews.com
To view or add a comment, sign in
-
The Poor Richard’s Almanac proverb, “time lost is never found again,” applies to head and neck cancer since treatment delays or discontinuations from severe oral mucositis are a risk factor for recurrence and shortened survival times. The Phase 2 clinical trial, KEVLARx will combine RRx-001 (nibrozetone) with cisplatin and radiotherapy to prevent or mitigate the toxicity of severe oral mucositis. Read more here: https://bit.ly/4dd8nlv.
To view or add a comment, sign in
-
-
In a multicenter, randomized Phase 3 trial, capecitabine and XELOX were found to have similar efficacy to PF in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). Notably, capecitabine demonstrated a lower incidence of severe adverse events compared to PF, suggesting it as a more tolerable alternative. Additionally, consolidation chemotherapy provided a significant survival benefit over DCRT alone. These findings may influence future treatment protocols for ESCC, emphasizing the potential for better patient outcomes with capecitabine-based regimens. #EsophagealCancer #Chemoradiotherapy #OncologyResearch #CancerTreatment #ClinicalTrials
To view or add a comment, sign in
-
-
NRG-LU008 is a #clinical trial for patients with locally advanced, inoperable, node-positive non-small cell #lungcancer (NSCLC) testing the + SBRT delivered to the primary lung tumor followed by RT & concurrent platinum-based chemotherapy. Learn more: https://ow.ly/GcAV50Q77T5
To view or add a comment, sign in
-
-
Immuneering! IMRX! Read below! Novel drug discovery!
We are pleased to announce that we have received IND clearance from the FDA for IMM-6-415, paving the way for the initiation of a Phase 1/2a clinical trial for the treatment of advanced RAF or RAS mutant solid tumors. We look forward to advancing this important program for solid tumor patients with any mutation in RAF, KRAS, NRAS, or HRAS into the clinic, with plans to begin dosing in early 2024. For details, see our press release: https://lnkd.in/ekjBT7hc #KRASmutations #RASmutations #TargetedOncology #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer
To view or add a comment, sign in
-
-
Summary: The article discusses the promising efficacy of a chemotherapy-free regimen combining eftilagimod alpha with pembrolizumab in patients with advanced PD-L1-negative head and neck squamous cell carcinoma
web link
assets.medpagetoday.net
To view or add a comment, sign in
-
The #KIT ligand #KITLG promotes portal vein tumor #thrombosis by up-regulating COL4A1 through STAT3-SMAD2 signaling in hepatocellular carcinoma https://lnkd.in/egPH4d6Y
To view or add a comment, sign in
-
-
Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq
To view or add a comment, sign in
-
-
📋 PD-1 inhibitors with chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, boost radiosensitivity, and improve local control for patients. 👉 Learn how the treatment can aid patients with #esophagealcancer:
Does Induction Immunotherapy Benefit Patients With Advanced Esophageal Cancer? | Docwire News
docwirenews.com
To view or add a comment, sign in